News & Updates
Filter by Specialty:
Glecaprevir/pibrentasvir shows favourable efficacy signals for paediatric HCV
Findings from the ongoing POLAC project demonstrate that treatment with the pangenotypic regimen comprising glecaprevir/pibrentasvir (GLE/PIB) for 8 weeks is highly effective against chronic hepatitis C virus (HCV) infection in children and adolescents. This regimen also showed a good safety profile.
Glecaprevir/pibrentasvir shows favourable efficacy signals for paediatric HCV
10 Jul 2024
9-month, oral modified treatment regimens make the grade in drug-resistant TB
Nine-month, fully oral modified short treatment regimens (mSTRs) consisting of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine or delamanid appear to yield high treatment success and good safety results in the treatment of patients with rifampicin-resistant, fluoroquinolone-susceptible tuberculosis (TB), according to a study.
9-month, oral modified treatment regimens make the grade in drug-resistant TB
04 Jul 2024
Risk of death 54 percent lower with remdesivir added for hospitalized COVID-19 patients on O₂ support
The inclusion of remdesivir in the SoC is significantly associated with a 54-percent lower risk of death at day 28 among hospitalized adults with COVID-19 who require O2 support, suggests a cross-study comparison that weight-balances patients from a clinical trial with those from a real-world study
Risk of death 54 percent lower with remdesivir added for hospitalized COVID-19 patients on O₂ support
01 Jul 2024
Antibiotics may promote development of Kawasaki disease
Use of antibiotics appears to increase the risk of Kawasaki disease (KD) in children, reveals a study. KD development is potentially driven by gut microbiota changes due to antibiotic use.